BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms - Fierce Pharma
BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms Fierce Pharma
Amgen Company News
Bristol Myers sues Amgen over proposed Opdivo biosimilar - Reuters
Bristol Myers sues Amgen over proposed Opdivo biosimilar Reuters
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
Bristol Myers sues Amgen over proposed Opdivo biosimilar - pharma.economictimes.indiatimes.com
Bristol Myers sues Amgen over proposed Opdivo biosimilar pharma.economictimes.indiatimes.com
From the Financial Crisis to the 2022 Bear Market, How Does Amgen Demonstrate Resilience? - NAI500
From the Financial Crisis to the 2022 Bear Market, How Does Amgen Demonstrate Resilience? NAI500
BMS, Ono sue to protect Opdivo from Amgen biosimilar - FirstWord PHARMA
BMS, Ono sue to protect Opdivo from Amgen biosimilar FirstWord PHARMA
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock - Yahoo Finance
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock Yahoo Finance
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022 - The Motley Fool
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022 The Motley Fool
Amgen hit with lawsuit over its proposed Opdivo biosimilar - Life Sciences IP Review
Amgen hit with lawsuit over its proposed Opdivo biosimilar Life Sciences IP Review
Bristol-Myers Looks To Block Amgen's Cancer Biosimilar - Law360
Bristol-Myers Looks To Block Amgen's Cancer Biosimilar Law360
5 Red Days In A Row: Amgen Stock Is Down 15% - Trefis
5 Red Days In A Row: Amgen Stock Is Down 15% Trefis
Bank of America Corp DE Invests $1.83 Billion in Amgen Inc. $AMGN - MarketBeat
Bank of America Corp DE Invests $1.83 Billion in Amgen Inc. $AMGN MarketBeat
Amgen stock heads into the open after a sharp drop - ad-hoc-news.de
Amgen stock heads into the open after a sharp drop ad-hoc-news.de
Amgen (AMGN) Gets FDA Nod To Cut IMDELLTRA Monitoring Time - simplywall.st
Amgen (AMGN) Gets FDA Nod To Cut IMDELLTRA Monitoring Time simplywall.st
Amgen Leads The Pack With First Filing For US Opdivo Biosimilar - insights.citeline.com
Amgen Leads The Pack With First Filing For US Opdivo Biosimilar insights.citeline.com
Amgen Inc. (NASDAQ:AMGN) Wins FDA OK To Cut IMDELLTRA Monitoring - tradingview.com
Amgen Inc. (NASDAQ:AMGN) Wins FDA OK To Cut IMDELLTRA Monitoring tradingview.com
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure - Yahoo Finance
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure Yahoo Finance
Amgen Drops 10% on a Trial It Didn't Even Run - Yahoo Finance
Amgen Drops 10% on a Trial It Didn't Even Run Yahoo Finance
Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance
Are Medical Stocks Lagging Amgen (AMGN) This Year? Yahoo Finance
Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential - Yahoo Finance
Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential Yahoo Finance
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca - Yahoo Finance
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca Yahoo Finance
Amgen Named Among World’s Most Impactful Companies 2026 by TIME - Amgen
Amgen Named Among World’s Most Impactful Companies 2026 by TIME Amgen
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question. - Yahoo Finance
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question. Yahoo Finance
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
Amgen (AMGN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Amgen (AMGN) Dips More Than Broader Market: What You Should Know Yahoo Finance
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Amgen Inc. stock underperforms Friday when compared to competitors MarketWatch
Why MrBeast, Stand Up To Cancer, and Amgen Joined Forces to Support Pediatric Cancer Research - Amgen
Why MrBeast, Stand Up To Cancer, and Amgen Joined Forces to Support Pediatric Cancer Research Amgen
Amgen Stock Signals Its Confidence. The Market Agrees. - Trefis
Amgen Stock Signals Its Confidence. The Market Agrees. Trefis
Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill - Reuters
Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill Reuters
Cholesterol drug setback casts doubt over multibillion-dollar race - CNBC
Cholesterol drug setback casts doubt over multibillion-dollar race CNBC
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - PR Newswire
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire
Corient Private Wealth LP Decreases Position in Amgen Inc. $AMGN - MarketBeat
Corient Private Wealth LP Decreases Position in Amgen Inc. $AMGN MarketBeat
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
Amgen discloses data breach involving patient health information - Reuters
Amgen discloses data breach involving patient health information Reuters
Bristol Myers, Ono Sue Amgen to Block Proposed Opdivo Biosimilar in US - Medical Dialogues
Bristol Myers, Ono Sue Amgen to Block Proposed Opdivo Biosimilar in US Medical Dialogues
Amgen CEO Bob Bradway's 2025 Letter to Shareholders - Amgen
Amgen CEO Bob Bradway's 2025 Letter to Shareholders Amgen
Amgen Named One of Newsweek’s Most Trustworthy Companies in America 2026 - Amgen
Amgen Named One of Newsweek’s Most Trustworthy Companies in America 2026 Amgen
FDA shortens monitoring for a lung cancer treatment. Amgen's first doses now take 6-8 hours. - Stock Titan
FDA shortens monitoring for a lung cancer treatment. Amgen's first doses now take 6-8 hours. Stock Titan
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
New data could widen use of AstraZeneca, Amgen immune disease drug - BioPharma Dive
New data could widen use of AstraZeneca, Amgen immune disease drug BioPharma Dive